Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
18 Agosto 2022 - 9:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the research and
discovery of new and effective treatments for psychiatric and
neurological disorders, today announced it will present the
preclinical proof of concept study results of its tolerizing
vaccine program in multiple sclerosis (“MS”) on August 30th at the
international conference “From Laboratory to Clinic: Medicine after
COVID” held at Trinity College, Oxford University, United Kingdom.
From Laboratory to Clinic is an annual
translational research conference established in 1984 that brings
together basic scientists, clinicians, and industry researchers to
explore how the latest discoveries in immunology and molecular
medicine can be applied to improve clinical medicine. During the
Symposium, Pasithea’s Chairman, National Academy of Sciences
Professor Lawrence Steinman, will be giving the opening keynote
lecture. Other speakers will include Dr. Carola Vinuesa, Professor
at the Francis Crick Institute in London; Dr. Gali Alter, Professor
of medicine at Harvard Medical School; Dr. Jeffrey Ravetch,
Professor and head of the Laboratory of Molecular Genetics and
Immunology at the Rockefeller University and Dr. Anne Schaefer,
Vice-chair of Neuroscience at the Icahn School of Medicine at Mount
Sinai.
“We look forward to presenting our data at this
important international conference alongside other world recognized
leading authorities in immunology and immunotherapy. The study
results support the Company’s commitment to the program and move us
further along our path to uncover new and effective treatments for
neurological disorders,” said Dr. Tiago Reis Marques, Chief
Executive Officer of Pasithea.
Date: |
Tuesday,
August 30, 2022 |
Time: |
9:00 a.m. - 9:50 a.m. ET |
Conference details.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
ContactDr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024